0001179110-18-007255.txt : 20180521 0001179110-18-007255.hdr.sgml : 20180521 20180521172152 ACCESSION NUMBER: 0001179110-18-007255 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180517 FILED AS OF DATE: 20180521 DATE AS OF CHANGE: 20180521 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Meury William CENTRAL INDEX KEY: 0001536778 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36867 FILM NUMBER: 18850620 MAIL ADDRESS: STREET 1: C/O FOREST LABORATORIES, INC. STREET 2: 909 THIRD AVENUE CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Allergan plc CENTRAL INDEX KEY: 0001578845 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CLONSHAUGH BUSINESS AND TECHNOLOGY PARK CITY: COOLOCK, DUBLIN STATE: L2 ZIP: D17 E400 BUSINESS PHONE: (216) 523-5000 MAIL ADDRESS: STREET 1: CLONSHAUGH BUSINESS AND TECHNOLOGY PARK CITY: COOLOCK, DUBLIN STATE: L2 ZIP: D17 E400 FORMER COMPANY: FORMER CONFORMED NAME: Actavis plc DATE OF NAME CHANGE: 20130930 FORMER COMPANY: FORMER CONFORMED NAME: Actavis Ltd DATE OF NAME CHANGE: 20130607 4 1 edgar.xml FORM 4 - X0306 4 2018-05-17 0 0001578845 Allergan plc AGN 0001536778 Meury William CLONSHAUGH BUSINESS AND TECHNOLOGY PARK, COOLOCK, CO. DUBLIN L2 D17 E400 IRELAND 0 1 0 0 EVP & Chief Commercial Officer Ordinary Shares, par value $0.0001 2018-05-17 4 M 0 1467 68.11 A 20369 D Ordinary Shares, par value $0.0001 2018-05-17 4 M 0 19785 68.11 A 40154 D Ordinary Shares, par value $0.0001 2018-05-17 4 S 0 24425 154.59 D 15729 D Incentive Stock Option 68.11 2018-05-17 4 M 0 1467 0 D 2018-12-05 Ordinary Shares 1467 0 D Non-Qualified Options to Purchase Common Stock 68.11 2018-05-17 4 M 0 19785 0 D 2018-12-05 Ordinary Shares 19785 0 D This exercise is pursuant to a previously established 10b5-1 Trading Plan dated November 16, 2017 for the Reporting Person. Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. This sale is pursuant to a previously established 10b5-1 Trading Plan dated November 16, 2017 for the Reporting Person. The options vested on December 6, 2015. The options vested in five equal installments on December 6, 2011, 2012, 2013, 2014 and 2015. /s/ A. Robert D. Bailey, Attorney-in-Fact for the Reporting Person 2018-05-21 EX-24 2 ex-24williammeury_poa.txt POWER OF ATTORNEY SECTION 16 William Meury With respect to holdings of and transactions in securities issued by Allergan plc (the "COMPANY"), the undersigned hereby constitutes and appoints the individuals named on SCHEDULE A attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned's true and lawful attorney-in-fact to: 1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the United States Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain and/or regenerate codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC; 2. execute for and on behalf of the undersigned, Forms 3, 4, and 5 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder; 3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and 4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his or her discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is any Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 3rd day of May, 2018. /S/ William Meury SCHEDULE A Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and Resubstitution 1. A. Robert D. Bailey, EVP & Chief Legal Officer and Corporate Secretary 2. Matthew Walsh, EVP & Chief Financial Officer 3. James DArecca, SVP, Chief Accounting Officer - Global 4. Kira Schwartz, Assistant Secretary